TY - JOUR T1 - Validation of Bupropion Hydroxylation as a Selective Marker of Human Cytochrome P450 2B6 Catalytic Activity JF - Drug Metabolism and Disposition JO - Drug Metab Dispos SP - 1222 LP - 1230 VL - 28 IS - 10 AU - Stephanie R. Faucette AU - Roy L. Hawke AU - Edward L. Lecluyse AU - Stacy S. Shord AU - Bingfang Yan AU - Ronald M. Laethem AU - Celeste M. Lindley Y1 - 2000/10/01 UR - http://dmd.aspetjournals.org/content/28/10/1222.abstract N2 - The purpose of this study was to establish bupropion (BUP) hydroxylation as a selective in vitro marker of cytochrome P450 (CYP) 2B6 catalytic activity. Among a panel of 16 human liver microsomes (HLMs), BUP hydroxylase activity varied 80-fold when assayed at 500 μM substrate and significantly correlated with CYP2B6 blotting density (r2 = 0.99) andS-mephenytoin N-demethylase activity (r2 = 0.98). Kinetic analysis of BUP hydroxylation was performed in a subset of seven HLMs representative of the 80-fold range in activity. Sigmoidal kinetics suggestive of allosteric activation was observed in five HLMs exhibiting low or high activity; the mean apparent Km for BUP hydroxylation in these HLMs (130 μM) was similar to theKm for cDNA-expressed CYP2B6 (156 μM). Nonsaturable, biphasic kinetics was observed in two HLMs exhibiting low activity. Among a panel of cDNA-expressed P450 isoforms, CYP2B6 and CYP2E1 demonstrated the highest rates of BUP hydroxylation at 12 mM BUP (7.0 and 2.4 pmol/min/pmol of P450, respectively). The relative contributions of CYP2B6 and CYP2E1 to BUP hydroxylation were estimated by using immunoinhibitory monoclonal antibodies (MAB) to these enzymes. MAB-2B6 produced 88% maximum inhibition of BUP hydroxylation when assayed at 12 mM BUP in a high activity HLM, whereas MAB-2E1 produced 81% maximum inhibition in a low activity HLM. However, negligible inhibition by MAB-2E1 was observed when low and high activity HLMs were assayed at 500 μM BUP. These results demonstrate selectivity of BUP hydroxylation for CYP2B6 at 500 μM BUP, thereby validating its use as a diagnostic in vitro marker of CYP2B6 catalytic activity. The American Society for Pharmacology and Experimental Therapeutics ER -